LCTX financials
Lineage Cell Therapeutics (LCTX) financials: revenue, profit and margins by year and quarter, the balance sheet and cash flow.
LCTX income statement, yearly
| Year | Revenue | Gross profit | Operating income | Net income | EPS |
|---|---|---|---|---|---|
| 2025 | $14.56M | – | -$36.62M | -$63.53M | -0.28 |
| 2024 | $9.50M | $9.16M | -$21.48M | -$18.61M | -0.09 |
| 2023 | $8.95M | $8.27M | -$24.73M | -$21.49M | -0.12 |
| 2022 | $14.70M | $13.97M | -$22.52M | -$26.27M | -0.15 |
| 2021 | $4.34M | $2.92M | -$49.21M | -$43.02M | -0.26 |
| 2020 | $1.83M | $1.44M | -$26.45M | -$20.65M | -0.14 |
- LCTX revenue was $14.56M in fiscal 2025, net income -$63.53M.
Updated 2026-11-17 17:46 UTC